[Featured Stock] Dio, a 'Big 3' in the Implant Industry... Rises on News of Management Rights Sale Reattempt
[Asia Economy Reporter Jang Hyowon] Dio is showing strong performance. This is interpreted as due to news that the management rights sale, which was canceled in August last year, is being reconsidered after about six months.
As of 9:24 AM on the 14th, Dio is trading at 23,750 KRW, up 5.09% compared to the previous day.
According to industry sources, Credit Suisse is recently contacting potential buyers to sell 29.6% of shares held by Dio's largest shareholder, Nice Investment Partners, and its affiliates. It is known that not only private equity funds (PEF) and financial investors (FI), but also some domestic large corporations are showing interest as strategic investors (SI) in acquiring Dio's management rights.
Hot Picks Today
Despite 10% Annual Interest, Russians Pull Out Cash as Fears of Deposit Nationalization Spread
- "Monami Posts a 10 Billion Won Deficit, But Consistently Awards 4.7 Billion Won in Contracts to the Third-Generation Family Company"
- "Can We Trust These Cars?"... China Flooded with New Models Amid 'Rushed Car' Controversy
- National Assembly Passes Series of Livelihood Bills... Restrictions on "Abusive Protests" Near Schools
- "Terrible Quality" Low-Budget Chinese Animation Makes Stunning $28 Million Box Office Turnaround
Dio was established in 1988 and is a company that produces medical devices and dental implant products. Its main product lines include four sectors: implants, Dionavi, digital orthodontic devices, and digital prosthetic solutions. In 2021, it recorded sales of 150 billion KRW and operating profit of 34.8 billion KRW. Since 2019, it has accelerated its entry into the European market by completing the establishment of subsidiaries in Portugal, Turkey, Italy, and Russia.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
